Popping-shoulder-900x500-e1513618300697.jpg

HSS Researchers Receive Grant for Clinical Trial to Improve Outcomes for Rotator Cuff Tears

Posted On December 18, 2017 By OrthoSpineNews In Sports Medicine, Top Stories /  

NEW YORK, Dec. 18, 2017 /PRNewswire-USNewswire/ — A multidisciplinary team led by Scott Rodeo, MD, and Christopher Mendias, PhD, at Hospital for Special Surgery (HSS) has been awarded the Orthopaedic Research and Education Foundation (OREF) Clinical Research Grant in Cellular Therapy in honor of James Urbaniak, MD in Collaboration with National Stem Cell Foundation (NSCF). The $800,000 grant will fund a clinical trial to determine if the use of stem cell therapy can improve outcomes for patients who suffer rotator cuff tears. To date, this is the largest grant given in OREF history.

Rotator cuff tears are one of the most prevalent musculoskeletal conditions yet surgical repair does not reverse muscle atrophy so patients may continue to feel weakness and pain even after surgery.

While surgical techniques have evolved over the years, there is still a high re-tear rate, which warrants more research to identify a better solution.

“The results of rotator cuff repair surgery are adversely affected by muscle atrophy and weakness, making it difficult for many patients to return to full function,” said Dr. Rodeo, co-principal investigator and sports medicine surgeon at HSS.

Previous studies have shown that stem cells that are harvested from body fat in the abdominal and thigh area can improve the regeneration of musculoskeletal tissues.  These cells, known as stromal vascular fraction cells (SVFCs), contain a population of pluripotent stem cells that can differentiate into skeletal muscle and tendon tissue. These cells also secrete anti-inflammatory and tissue regeneration molecules.

The grant will move research ahead to a phase II clinical trial to evaluate the safety and efficacy of SVFCs in improving outcomes for patients who undergo arthroscopic surgical repair for rotator cuff tears.

“This study may be the first to determine if stem cells from a patient’s own adipose tissue can improve outcomes after rotator cuff repair,” said Dr. Mendias, co-principal investigator and associate scientist at HSS. “We believe that the patients who receive SVFCs may see improved function and demonstrate improved tissue healing on both clinical imaging and tissue histological studies.”

Over 50 patients will be enrolled in the study, with HSS following patients for two years to track strength and range of motion measurements, imaging assessments of muscle and tendon regeneration, and patient-reported outcome scores.  In order to evaluate return to normal function, the primary outcome measure will be shoulder strength.

“If we demonstrate that this cell therapy is successful, then there is a clear justification for a pivotal phase III clinical trial in patients with rotator cuff tears,” added Dr. Rodeo. “We are very excited about the journey ahead.”

The other HSS investigators are Russell F. Warren, MD; Frank A. Cordasco, MD; Hollis G. Potter, MD; Matthew F. Koff, PhD; and Ogonna Kenechi Nwawka, MD.

About Hospital for Special Surgery
Hospital for Special Surgery (HSS) is the world’s leading academic medical center focused on musculoskeletal health. HSS is nationally ranked No. 1 in orthopedics and No. 3 in rheumatology by U.S. News & World Report (2017-2018), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital’s research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. HSS has locations in New York, New Jersey and Connecticut.
www.hss.edu

 

SOURCE Hospital for Special Surgery

Related Links

http://www.hss.edu

Read More
maxresdefault.jpg

Orthocell Granted European Tendon Regeneration Patent

Posted On December 15, 2017 By OrthoSpineNews In Regulatory, Sports Medicine /  

December 14, 2017

PERTH, Australia–(BUSINESS WIRE)–Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has been granted a key European Patent. The patent is entitled ‘Culture medium, culturing method and use of tenocytes’ protecting the method of manufacturing tendon regeneration cells (Tenocytes) to form the Autologous Tenocyte Implantation (Ortho-ATI®) product. The patent expires in 2027 and provides additional important intellectual property (IP) to protect Orthocell’s tendon repair applications, now granted in EU, USA, China, Australia, Singapore, Hong Kong and New Zealand.

“Securing this patent for tendon repair in Europe is another milestone in strengthening our IP position as we drive our novel world leading tendon repair product into the global market. Orthocell is focused on building and maintaining patent protection for our regenerative medicine technologies and treatment processes,” Orthocell Managing Director Paul Anderson said.

Global IP protection for Ortho-ATI® further underpins the international rollout of Orthocell’s world leading tendon repair technology. Orthocell is well positioned to commercialise Ortho-ATI® with mature manufacturing facilities in place, proven safety and efficacy, published clinical data and a clear pathway to market.

Orthocell maintains an active program of patenting, with ownership of 29 granted patents across the Ortho-ATI®, Ortho-ACI® and CelGro® technologies, and related methods of treatment and manufacturing.

About Ortho-ATI®:

Ortho-ATI® is a world leading breakthrough in regenerative medicine – a novel, cell therapy developed to treat chronic degenerative tendon injuries (tendinopathy / tendonitis), it can be utilised in both surgical and non-surgical applications.

  • Tendon injury and its end point, tendinopathy, are a common cause of occupational and sporting disability reported to affect 1% to 3% of the general population every year
  • Significant financial burden to the public health care system expected to increase as the population ages, as a result, new treatments are required that are safe, effective and cost efficient
  • Ortho-ATI® meets the market need by enabling the accelerated regeneration of injured tendons, directly addressing the underlying cause of injury, replenishing degenerative tissue with healthy mature tendon cells (known as tenocytes)
  • Extensive clinical validation with published clinical data up to 4.5 years post treatment in leading peer reviewed journals, (e.g. American Journal Sports Medicine) clearly demonstrating durability and efficacy as the leading tendon regeneration treatment

Contacts

General enquiries
Orthocell Limited
Paul Anderson, +61 8 9360 2888
Managing Director
paulanderson@orthocell.com.au
or
Investor and Media enquiries
WE Buchan
Ben Walsh, + 61 411 520 012
bwalsh@buchanwe.com.au

Read More
sports1-A-1.jpg

Sports Medicine Market by Product, Application & Region – Global Forecast to 2022

Posted On December 11, 2017 By OrthoSpineNews In Sports Medicine /  

DUBLIN, Dec. 11, 2017 /PRNewswire/ —

The “Sports Medicine Market – Global Forecast to 2022” report has been added to Research and Markets’ offering.

The global sports medicine market is projected to reach USD 8.24 Billion by 2022 from USD 5.78 Billion in 2017, at a CAGR of 7.4% during the forecast period. The increasing incidence of sports injuries, continuous influx of new products and treatment modalities, and developments in the field of regenerative medicine are some of the major factors driving the growth of the global sports medicine market.

The sports medicine market is segmented on the basis of product, application, and region. On the basis of product, the global market is segmented into body reconstruction products, body support & recovery products, and accessories. The body reconstruction products segment is further categorized into implants, fracture & ligament repair devices, arthroscopy devices, prosthetics, and orthobiologics. The orthobiologics segment is expected to grow at the highest CAGR during the forecast period. The high growth in this segment can be attributed to the recent developments in regenerative medicine, allografts, and stem cell therapy.

The body support & recovery products segment is further divided into braces and supports, compression clothing, and physiotherapy equipment. The physiotherapy equipment segment is further categorized into thermal therapy, electrostimulation, and other therapies.

Based on application, the market is segmented into shoulder, foot and ankle, elbow & wrist, back & spine, hip & groin, knee, and other injuries (head, face, and finger injuries). In 2017, the knee injuries segment is estimated to command the largest share of the sports medicine market. Growth in the knee injuries segment can be attributed to the increasing participation in sports like football and basketball at a younger age, resulting in high prevalence of knee injuries.

The elbow and wrist injuries segment is estimated to register the highest CAGR during to forecast period. This can be attributed to the increasing number of injuries in sports, like rowing, racquet sports, and golf, where there is a repetitive overuse of elbow and wrists.

Companies Mentioned 

  • Arthrex
  • Breg
  • Conmed
  • Depuy Synthes Companies
  • Djo Global
  • Medtronic
  • Mueller Sports Medicine
  • Performance Health International Limited
  • Rti Surgical
  • Smith & Nephew
  • Stryker
  • Wright Medical Group
  • Zimmer Biomet

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Sports Medicine Market, By Product

7 Sports Medicine Market, By Application

8 Sports Medicine Market, By Region

9 Competitive Landscape

10 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/4f5vzv/sports_medicine

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Read More
Rotation_CollagenImplant_WEB-2.png

Rotation Medical Bioinductive Implant Promotes Consistent Rotator Cuff Healing, Mitigates Tear Progression

Posted On November 30, 2017 By OrthoSpineNews In Biologics, Sports Medicine, Top Stories /  

November 30, 2017

PLYMOUTH, Minn.–(BUSINESS WIRE)–Rotation Medical Inc., a medical device company focused on developing new technologies to treat rotator cuff disease, today announced results of a study published online in the Journal of Shoulder and Elbow Surgery that shows the company’s Bioinductive Implant consistently heals rotator cuff tears and mitigates tear progression. The Rotation Medical Bioinductive Implant is part of the company’s novel rotator cuff system for rotator cuff repair and a new alternative to traditional surgical repair.

“Partial thickness rotator cuff tears do not heal spontaneously and have a high propensity to increase in size and/or develop into full-thickness lesions,” said Theodore F. Schlegel, MD, lead investigator of the study and orthopedic surgeon at Steadman Hawkins Clinic Denver. “This study shows that the Bioinductive Implant not only repairs the tear and increases tendon thickness, but it also prevents tear progression. In addition, because the native tendon footprint remains intact around the location of the defect, the Bioinductive Implant may accelerate rehabilitation and recovery as compared with more conservative postoperative management when partial thickness lesions are taken down and repaired as full thickness tears.”

The study enrolled 33 patients with chronic, degenerative, intermediate- (n=12) to high-grade (n=21) partial-thickness tears (11 articular, 10 bursal, four intra-substance, eight hybrid) of the supraspinatus tendon. Clinical outcomes were assessed using American Shoulder and Elbow Surgeons (ASES) and Constant-Murley scores preoperatively and at three and 12 months postoperatively. Magnetic resonance imaging (MRI) was performed to assess postoperative tendon healing and thickness at the original tear site. One-year results of the multi-center study include:

  • Clinical scores improved significantly (p<0.0001), and mean tendon thickness increased by 2.0 mm (p<0.0001); new tissue was indistinguishable from the underlying tendon.
  • 94 percent of patients experienced complete healing or considerable reduction in defect size; consistent partial to complete fill-in of the original bursal, intrasubstance and articular partial-thickness tear defects were observed as early as three months postoperatively, with sustained efficacy through 12 months.
  • 94 percent of patients either agreed or strongly agreed that they were satisfied with the results of their surgery.
  • No tears progressed to full-thickness in patients who followed the postoperative rehabilitation protocol.
  • No serious adverse events related to the implant were reported.

“In addition to further demonstrating that our Bioinductive Implant increases tendon thickness and prevents re-tears, we are pleased that the majority of patients in this study said they were satisfied with the results of their rotator cuff surgeries,” said Martha Shadan, president and CEO of Rotation Medical. “As health systems transition to value-based care, data like these are becoming increasingly necessary to demonstrate the effectiveness of medical devices on indicators such as patient satisfaction, in addition to key health economic drivers that we are measuring in our REBUILD Registry Study.”

The study, “Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multi-center study,” adds to the growing body of literature supporting the use of the Rotation Medical Bioinductive Implant as a novel treatment for rotator cuff injury. Additional publications and information about the Rotation Medical rotator cuff system are available on the company’s website.

About Rotator Cuff Tears
Rotator cuff damage is the most common source of shoulder pain, affecting more than 4 million people annually in the U.S. Traditional approaches to treating degenerate or torn rotator cuffs often do not address the poor quality of the underlying tendon tissue, and a significant number of these tendons, after standard treatment, either degenerate further and/or re-tear.

About the Rotation Medical Bioinductive Implant
Cleared by the U.S. Food and Drug Administration in March 2014, the Rotation Medical Bioinductive Implant is designed to address both the biomechanics and biology required to heal a rotator cuff tendon tear by inducing new tissue growth at the site of implantation, resulting in increased tendon thickness and healing of tendon defects with new tissue growth. The collagen-based implant is about the size of a postage stamp and it is part of the Rotation Medical rotator cuff system, which also includes disposable instruments that allow the arthroscopic procedure to be performed easily and quickly. For important safety information, visit http://rotationmedical.com/our-solution/risks/.

About Rotation Medical
Rotation Medical Inc. was founded in 2009 and is committed to improving the treatment of rotator cuff disease with the Rotation Medical rotator cuff system, a breakthrough technology that has the potential to prevent rotator cuff disease progression and reduce re-tears by inducing the growth of new tendinous tissue. The company is privately held and funded by New Enterprise Associates (NEA), Life Sciences Partners (LSP) and Pappas Ventures. For more information, visit http://www.rotationmedical.com/.

Contacts

Merryman Communications
Joni Ramirez, 323-532-0746
joni@merrymancommunications.com

Read More
Orthopediatrics.png

OrthoPediatrics Corp. to Highlight its Products at the 14th Annual International Pediatric Orthopaedic Symposium

Posted On November 27, 2017 By OrthoSpineNews In Extremities, Spine, Sports Medicine /  

WARSAW, Ind., Nov. 27, 2017 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ:KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, announced today that it is a Platinum sponsor of the 14th Annual International Pediatric Orthopaedic Symposium (IPOS), taking place November 28 to December 2, 2017 in Orlando, Florida.  The IPOS meeting, presented by the Pediatric Orthopaedic Society of North America (POSNA) and the American Academy of Orthopaedic Surgeons (AAOS), brings together hundreds of pediatric orthopedic surgeons from around the world.

As part of OrthoPediatrics’ commitment to leading innovation in pediatric orthopedics and fostering clinical education, the company is actively engaged in all aspects of the meeting.  This includes sponsoring a pre-course meeting on “The Surgical Treatment of Hip Dysplasia in Older Children and Adolescents.”  The Company will also host four interactive workshops, highlighting new technology and surgical techniques in Trauma, Deformity Correction, Sports Medicine/Soft Tissue Repair and Scoliosis care.

Mark Throdahl, President and CEO of OrthoPediatrics, said, “OrthoPediatrics’ goal is to advance the field of pediatric orthopedics with the broadest and most innovative product line in our industry.  Our surgical systems, coupled with our focus on clinical education, are at the very core of our business.  We are excited for our continued partnership with organizations like POSNA and look forward to returning to the IPOS meeting for another successful year.”

OrthoPediatrics will be highlighting its products at booth #104 at the IPOS meeting.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is the only diversified orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market. OrthoPediatrics is dedicated to the cause of improving the lives of children with orthopedic conditions. OrthoPediatrics currently markets 22 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma & deformity, complex spine and ACL reconstruction procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 35 countries outside the United States.

Investor Contact
The Ruth Group
Zack Kubow
(646) 536-7020
zkubow@theruthgroup.com

Read More
OrthoPediatrics-offices.png

OrthoPediatrics Corp. to Start Distributing Bioretec Devices via Private Label

Posted On November 13, 2017 By OrthoSpineNews In Biologics, Extremities, Sports Medicine, Top Stories /  

WARSAW, Ind., Nov. 13, 2017 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ:KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, and Bioretec Ltd. (“Bioretec”), announced today that they have amended their existing distribution agreement in order for OrthoPediatrics to market and sell Bioretec’s unique, bioresorbable orthopaedic bone and soft-tissue fixation implants under the OrthoPediatrics brand, TorqLoc™. Bioretec’s bioresorbable implants are ideal for repairing musculoskeletal defects of children and young people. Treatment of musculoskeletal defects and trauma related bone and soft-tissue injuries are steadily increasing, as well as the need for surgeries related to treating such conditions. Bioretec’s fully bioresorbable implants have shown excellent results in repairing the growing bones of children and young people.

“We are excited to start OrthoPediatrics’ private label collaboration, whose enthusiasm towards developing and improving surgical care for children, we admire.  Our products are ideal for surgeries of children, since the bioresorption of our implants eliminates the need for secondary removal operation after the healing of musculoskeletal tissues. This is especially important with children, for whom the risks and inconveniences associated with surgical procedures are much higher,” commented Tomi Numminen, CEO of Bioretec.

OrthoPediatrics’ Vice President for Trauma & Deformity Correction, Joe Hauser, added, “This evolving strategic partnership and collaboration with Bioretec represents another area for tremendous growth within OrthoPediatrics’ portfolio.  The TorqLoc™ screw portfolio will provide a truly innovative option for many unmet pediatric orthopedic sports and tissue repair surgical needs.  In addition to OrthoPediatrics’ all epiphyseal ACL system, we now can help our surgeon partners with MPFL, foot, shoulder, and hand solutions by providing this new generation bioabsorbable implant offering.”

About Bioretec
Bioretec Ltd. is a Finnish material technology company focused on the development, manufacturing and marketing of bioabsorbable, bioactive and drug-releasing surgical implants for orthopedic, trauma and sport medicine surgeries. Bioretec implants, designed and manufactured in Finland, have been used in 33 countries, including United States, China, Russia, UK, Germany, Italy and Spain.

About OrthoPediatrics Corp. 
Founded in 2006, OrthoPediatrics is the only diversified orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market. OrthoPediatrics is dedicated to the cause of improving the lives of children with orthopedic conditions. OrthoPediatrics currently markets 22 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma & deformity, complex spine and ACL reconstruction procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 35 countries outside the United States.

Investor Contact
The Ruth Group
Zack Kubow
(646) 536-7020
zkubow@theruthgroup.com

Read More
PR-Image_TP-e1509639000345.png

Consensus Orthopedics launches TracPatch Australia at the Australian AOA meeting in partnership with CUER

Posted On November 2, 2017 By OrthoSpineNews In Sports Medicine, Top Stories /  

SACRAMENTO, CALIF. (PRWEB) NOVEMBER 01, 2017

Consensus Orthopedics, developer of the latest wearable technology, TracPatch™, has partnered with Neil Thomas and Peter Mackie of CUER, who have come together to cofound TracPatch Australia to distribute this wearable technology throughout Australia and New Zealand. The Australian market is in need of a device that will allow healthcare providers the ability to plan and monitor their patients’ orthopedic recovery. TracPatch can also be applied in ethics studies related to total knee replacements and in conjunction with sports injury reconstruction surgery.

Michael T. Droege, Vice President of Global Business Development, says “Just the idea that both Peter Mackie and Neil Thomas have collaborated together to put all of their career experiences to create TracPatch Australia is an amazing opportunity. We are extremely fortunate to have them as part of our global TracPatch team.”

TracPatch™ is revolutionizing evidence-based surgical care management in orthopedics. The changing dynamics of healthcare has called for transforming patient care through connected health solutions. TracPatch is a cutting-edge remote monitoring device designed to make recovering at home easily accessible, connected, and more predictable. The development of TracPatch, with its availability worldwide, will revolutionize the way data-capturing is used in orthopedics. Surgeons and healthcare providers will be able to monitor their patients in real time during the post-acute care period following surgery. Through data collection, monitoring, and analysis, TracPatch™ ensures patients will receive effective care based on their individual needs.

TracPatch Australia will be the official Australia and New Zealand distributor. TracPatch Australia aims to develop business opportunities throughout the Oceania region. Together, Consensus Orthopedics and Tracpatch Australia presented TracPatch at the Australian Orthopedic Association Annual Scientific Meeting on 8-12 October 2017. TracPatch was well received to the international audience as an exceptional solution to post-surgical monitoring in orthopedics and as a market leader in Australia.

Neil Thomas, Business Development Manager at CUER, says “The need for not only remote monitoring of patients but of evidence based care management makes TracPatch a truly unique product. Australia is ready for an innovative way to create new care standards in orthopedics and TracPatch can help alleviate costs and unnecessary burdens to our healthcare system.”

Peter Mackie, Principle at CUER, states “TracPatch can dramatically shift how healthcare providers approach total joint surgeries in the future. Being able to monitor your patients and proactively get ahead of potential issues involved during a post-acute care period is a tremendous advantage. We are excited to be offering this new product to all Australian healthcare providers and we are looking forward to the future of orthopedics.”

For more Information on Tracpatch Australia please contact Neil Thomas at neil.thomas@cuer.com.au

About Consensus® Orthopedics, Inc.
Consensus Orthopedics was founded in 1992 as a medical device consulting company located in California. In 1996, Consensus Orthopedics acquired US Medical Products becoming a global manufacturer of reliable large joint orthopedic devices. Since 1996, Consensus Orthopedics has been providing the orthopedic industry with exceptional hip and knee joint replacement devices. Its signature knee system, the Consensus Knee System, has over 20 years of reliable and reproducible results. With a deep understanding of the orthopedic industry, Consensus launched its innovative TracPatch Technology division focusing on orthopedic wearable technology, which combines Consensus Orthopedics 25 years of orthopedic experience with innovative Big Data capabilities. TracPatch is a revolutionary new device empowering at-home patient recovery and remote monitoring for effective managed care. With a focus on evidence based medicine, Consensus Orthopedics is changing patient care and the future of orthopedics. Learn more at http://www.consensusortho.com.

About CUER Australia
CUER is a well connected and highly motivated company determined to be the market leaders in wearable technology in Australasia. CUER was founded with the purpose of developing business opportunities and sourcing new devices that are at the cutting edge of technology.

Read More
Physicians-WideImage-RepairTears-2015.png

Use of Ceterix NovoStitch® Plus System for Repair of Horizontal Meniscus Tears Supported by Three New Studies

Posted On October 31, 2017 By OrthoSpineNews In Sports Medicine /  

October 30, 2017

FREMONT, Calif.–(BUSINESS WIRE)–Ceterix® Orthopaedics today announced the publication of three new studies in the journal Arthroscopy Techniques supporting the use of the company’s NovoStitch® Plus device for the repair of horizontal cleavage meniscal tears:

“These publications illustrate the growing recognition that horizontal meniscus tears, previously deemed irreparable, can in fact be repaired with advanced technology,” said Dr. Kenneth Brooks, orthopaedic surgeon and author of one of the reports. “The NovoStitch Plus has given surgeons increased flexibility to develop advanced meniscal repair techniques specifically designed to treat horizontal tears. This allows us to preserve the meniscus in more patients, reducing the likelihood of developing arthritis or requiring knee replacement surgery later in life.”

Patients with meniscus tears often undergo meniscectomy – total or partial removal of the meniscus – due to the difficulty of access and limitations of current arthroscopic instruments. However, meniscectomy significantly increases the risk of arthritis or total knee replacement later in life.1 In contrast, meniscus repair, a procedure in which the tear is sutured and allowed to heal naturally, is associated with improved long-term outcomes and overall cost savings relative to meniscectomy.2 Meniscus surgery is the single most common arthroscopic procedure in the United States, with roughly one million performed annually.

The NovoStitch Plus device allows orthopaedic surgeons to address horizontal, radial, and other complex meniscal tears in ways not previously possible. The system enables the placement of a circumferential compression stitch around the meniscus, which provides uniform compression during healing and allows orthopaedic surgeons to treat these complex injuries.

About Ceterix Orthopaedics

Ceterix® Orthopaedics develops surgical tools that expand and improve what is possible for physicians who treat soft tissue joint injuries such as meniscus tears. Founded in 2010 with the vision of improving outcomes of arthroscopic procedures, Ceterix’s novel meniscal repair system enables surgeons to place suture patterns that were previously only possible in open procedures, or not at all. The NovoStitch Plus meniscal repair system has received 510k clearance in the United States and is indicated for approximation of soft tissue in meniscal repair procedures. The company is based in Fremont, Calif. and is backed by investors Versant Ventures, 5AM Ventures and CRG. For more information, please visit www.ceterix.com.

1 Papalia, R. et. al. Meniscectomy as a risk factor for knee osteoarthritis: a systematic review. British Medical Bulletin. 2011; 99:89 – 106.

2 Feeley, B. et. al. The Cost-Effectiveness of Meniscal Repair versus Partial Meniscectomy: A Model-based Projection of Clinical Outcomes and Costs in the United States Healthcare System. ISPOR Annual Meeting 2015.

Contacts

For Ceterix Orthopaedics
Jessica Volchok, 310-849-7985
jessica@healthandcommerce.com

Read More
tenex-health-1.jpg

Tenex Health Announces Executive Team Changes

Posted On October 19, 2017 By OrthoSpineNews In Sports Medicine /  

October 18, 2017

LAKE FOREST, Calif.–(BUSINESS WIRE)–Tenex Health, Inc., a privately held provider of minimally invasive solutions for chronic tendon pain, announced today that its Board of Directors has appointed William “Bill” Maya as the Company’s President and Chief Executive Officer, effective October 9, 2017. Mr. Maya will replace Bernard Morrey, M.D., who will step down as interim Chief Executive Officer and resume his previously held role as Chief Medical Officer. The Company also announced today that Leslie “Les” Cross has been appointed to its Board of Directors.

Bill Maya Appointed CEO

Mr. Maya has spent more than three decades successfully leading, innovating and growing medical device and healthcare organizations. He has unique, demonstrated experience identifying and capitalizing on business opportunities, including guiding a number of companies through critical transformation periods. He has built long-term customer, physician and distributor relationships in the domestic and international markets and has a demonstrated track record of re-focusing organizations for growth and profitability. Throughout his career, Mr. Maya has built top performing leadership teams and instilled a winning culture focused on building long-term value for stakeholders.

Most recently Mr. Maya served as Chief Executive Officer at OrthAlign, Inc. During his six-year tenure, he productively first fixed and then successfully grew the organization globally, secured multiple millions of venture capital financing and led the commercialization efforts to support the launch of its next generation product. Prior to OrthAlign Inc., Mr. Maya spent over twenty years serving as Chief Executive Officer at such innovative companies as Vestara, LLC, DataLabs, Inc., Advanced Spine Fixation Systems, Inc., and Birtcher Medical Systems. Mr. Maya received a B.S. in Biology from Saint Joseph’s College. Mr. Maya currently also serves on the Board of Directors of three other companies.

Chuck Grant, Chairman of the Tenex Health Board of Directors, said, “Bill brings more than 35 years of strong operational and market growth experience, as well as sales and distribution expansion expertise to Tenex. His extensive leadership experience in the medical device industry, coupled with his strong track record of turn-arounds and delivering results, will be invaluable to Tenex. Bill is an excellent addition to Tenex and I look forward to working with him as we execute on our strategy for future growth.”

Mr. Grant added, “The Board would also like to thank Dr. Bernard Morrey for his leadership over the past year as interim CEO while we engaged in our executive search. We appreciate his guidance and dedication.”

Mr. Maya said, “I am honored with the appointment to lead Tenex as CEO. I have spent most of my career helping medical device companies transform their operations and realize their true potential. Tenex has pioneered a safe, minimally invasive solution for chronic tendon pain that is designed to provide relief to patients and ultimately, improve their lifestyles. With over 70,000 cases performed to date and proven clinical evidence, I believe there is significant opportunity ahead for Tenex. I am excited to work with the management team, Les and the Board of Directors, and our employees to capitalize on the opportunity and unlock stakeholder value.”

Les Cross Appointed to the Board of Directors

“We are extremely pleased to welcome Les to Tenex Health’s Board of Directors,” said Mr. Grant. “Les is an accomplished business leader and experienced board member in the medical device industry. We are confident that he will add great value to our Board of Directors and that Tenex will benefit from his insights and contributions as we execute on our strategy for long-term success.”

Mr. Cross said, “I am delighted to join the Tenex Board of Directors. With over 20 million Americans suffering from tendon pain, I believe that Tenex is well-positioned to become a compelling solution for physicians and make a real difference in patient’s lives. I look forward to working with Bill and the rest of the Board as he leads Tenex through this exciting new phase of growth for the Company.”

Mr. Cross brings more than 30 years of medical device and executive experience throughout his distinguished career to the Tenex Board. Previously, Mr. Cross served as the Chairman of the Board of Directors of Alphatec Spine from 2011 to 2017. From 2012 to 2014 he also served as Alphatec Spine’s Chief Executive of Officer. Prior to 2011, Mr. Cross served as President and Chief Executive Officer of DJO Global, Inc., where he held several principal executive roles since 1995. From 1990 and 1994, Mr. Cross held the position of Senior Vice-President of Marketing and Business Development of the Bracing and Support Systems division of Smith & Nephew. He was Managing Director of two different divisions of Smith & Nephew from 1982 to 1990. Mr. Cross earned a diploma in medical technology from Sydney Technical College in Sydney, Australia and studied business at the University of Cape Town in Cape Town, South Africa. Mr. Cross currently also serves on the Board of Directors of two other companies.

About Tenex Health, Inc.

Tenex Health, Inc. develops innovative surgical instruments for the treatment of tendon pain due to repetitive motion injuries. The Company’s proprietary technology is designed to cut and remove diseased soft tissue in a minimally invasive outpatient setting. Since the surrounding healthy tendon tissue is not disturbed, patients feel less discomfort and enjoy faster recovery times versus traditional open surgical procedures.

Additional information can be found at www.tenexhealth.com.

Contacts

Tenex Health, Inc.
Bill Maya
949.454.7500 / 855.2 TENDON
info@tenexhealth.com
www.tenexhealth.com

Read More
22450616_10212531622318839_424332193_o-e1507752712736.jpg

Oska Wellness Wins TechCo’s 2017 Startup of the Year Competition

Posted On October 12, 2017 By OrthoSpineNews In Extremities, Sports Medicine, Top Stories /  

October 11, 2017/Adam Rowe

Oska Wellness, a health-tech, wearable pain relief device startup based out of Carlsbad, CA, is the 2017 Startup of the Year winner.

The announcement, made at the Innovate Celebrate conference held by TechCo in partnership with CTA, came following a three-day event attended by 100 startup semifinalists, and eventually narrowed down to five finalist startups today. Of all contestants at the wide-sweeping startup competition, Oska Wellness has officially risen to the top.

As the first-place winner, Oska Wellness will receive a prize package worth potentially $150,000 and from a list of companies including Start Co., 500 Startups, Techstars, Dreamit Ventures, Business Blocks, American Airlines, and Moo.

Oska Wellness Is the 2017 Startup of the Year

Oska Wellness designs a technology that can help areas of the body prone to injury and degeneration. You can listen to their final competition pitch below, and can watch the other four startup of the year finalists pitch here.

 

READ THE REST HERE

Read More